Photo Credit: Data on File. Certis Oncology (2024). The conventional drug development pipeline has delivered incredible pharmaceutical successes and blockbusters. But, recently, appreciation for the growing number of failed drug candidates that...
Certis Oncology Solution's Self-Proclaimed Poster Boy: Jeffrey Alan Dinkin
It started with back pain.
RAS Mutations in Cancer: Emerging Drug Development Strategies
For four decades, the causal link between RAS mutations in cancer – including the KRAS, HRAS, and NRAS genes – has been well-accepted. But for almost as long, oncology drug development has struggled to develop RAS inhibitors, and many had long...
The Power of Predictive AI Models: Revolutionizing Cancer Research
Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied...
Functional Precision Oncology: Filling the Gap Left By Genomics-Based Approaches
Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor...
How to Overcome the Translation Gap in Cancer Research
Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope...
Mimicking the "Seed and Soil:" The State of PDX Models of Breast Cancer Metastases
Why do the quaintest analogies stick to biology’s most morbid phenomena? Look no further than English surgeon Stephen Paget’s “seed and soil” model for breast cancer metastasis for a prototypical example. In his 1889 publication in the Lancet, Paget...
New Certis Whitepaper: Bringing Certainty to PDX Model Characterization
EXECUTIVE SUMMARY Patient-derived xenograft (PDX) models are indispensable for translational cancer research. However, public and private PDX tumor banks may lack standard quality controls, which may lead to genomic and transcriptomic...
Improving Drug Development and Glioblastoma Xenograft Models
Overcoming Glioblastoma Multiforme (GBM) Drug Development Challenges With Glioblastoma Xenograft Models Primary brain tumors are highly heterogeneous tumors that cause significant morbidity and mortality. An estimated 700,000 Americans are living...
Developing Clinically Relevant Metastatic Colorectal Cancer Models: From Carcinogens to Xenografts
Colorectal cancer (CRC) is common and deadly, making up an estimated 7.9% of all new cancer cases and 8.7% of all cancer deaths in the U.S. last year.1 Cancer mortality often results from metastasis, which for colorectal cancer, happens frequently; ...